ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

170.22
-0.99
( -0.58% )
Updated: 12:56:05

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
170.22
Bid
170.12
Ask
170.61
Volume
165,602
168.41 Day's Range 172.93
93.95 52 Week Range 191.78
Market Cap
Previous Close
171.21
Open
172.56
Last Trade
6
@
170.12
Last Trade Time
12:56:05
Financial Volume
$ 28,473,068
VWAP
171.9367
Average Volume (3m)
304,423
Shares Outstanding
28,558,440
Dividend Yield
-
PE Ratio
444.85
Earnings Per Share (EPS)
0.38
Revenue
50.7M
Net Profit
10.93M

About Krystal Biotech Inc

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was $171.21. Over the last year, Krystal Biotech shares have traded in a share price range of $ 93.95 to $ 191.78.

Krystal Biotech currently has 28,558,440 shares outstanding. The market capitalization of Krystal Biotech is $4.86 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 444.85.

KRYS Latest News

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK, June 7, 2024 NEW YORK, June 7, 2024 /PRNewswire/...

Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference

PITTSBURGH, June 05, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting...

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

Index Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices Rise

U.S. index futures indicate a positive opening in Monday’s pre-market, extending the robust gains achieved last week. At 06:36 AM, the futures for the Dow Jones Industrial Average...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-9.99-5.54353254536180.21181.25168.41465879174.79624178CS
46.33.84333821376163.92191.78154.5391506173.45029797CS
12-6.93-3.91193903472177.15191.78144.0001304423168.52431121CS
2654.5747.1854734112115.65191.78107.5349881154.02585796CS
5246.3137.3739004116123.91191.7893.95320048135.95465184CS
156104.8160.1956588265.42191.7838.8563254501100.25172974CS
260141.22486.96551724129191.7828.4421600985.80816946CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.8292
(175.48%)
286.65M
SHCRSharecare Inc
$ 1.365
(76.27%)
34.62M
NXLNexalin Technologies Inc
$ 1.8999
(72.72%)
41.28M
SPECSpectaire Holdings Inc
$ 0.5546
(63.12%)
58.85M
MINMMinim Inc
$ 3.81
(33.22%)
41.58M
KAVLKaival Brands Innovations Group Inc
$ 1.45
(-49.48%)
3.29M
PBMPsyence Biomedical Ltd
$ 0.3949
(-34.18%)
2.22M
FLFVFeutune Light Acquisition Corporation
$ 6.00
(-28.83%)
36.67k
FBLGFibroBiologics Inc
$ 4.18
(-21.87%)
272.72k
RELIReliance Global Group Inc
$ 0.472
(-21.84%)
7.51M
NVDANVIDIA Corporation
$ 127.62
(-2.42%)
293.18M
AREBAmerican Rebel Holdings Inc
$ 0.8292
(175.48%)
286.65M
CRKNCrown Electrokinetics Corporation
$ 0.0403
(-19.40%)
135.18M
NKLANikola Corporation
$ 0.3636
(10.32%)
121.51M
ASTIAscent Solar Technologies Inc
$ 0.112
(3.80%)
113.61M

KRYS Discussion

View Posts
Monksdream Monksdream 2 months ago
KRYS 10Q due 5/6
👍️0
Monksdream Monksdream 2 months ago
KRYS over $30
👍️0
Monksdream Monksdream 4 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 12 months ago
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 3 years ago
Moving nicely today...
👍️0
wiredawg wiredawg 3 years ago
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 3 years ago
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 3 years ago
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 3 years ago
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 3 years ago
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 3 years ago
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 3 years ago
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 3 years ago
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 3 years ago
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 3 years ago
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 3 years ago
3rd post
👍️0
crudeoil24 crudeoil24 3 years ago
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 5 years ago
..
👍️0

Your Recent History

Delayed Upgrade Clock